Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis

Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis

Bibliographic Details
Main Authors: N Fleeman, A Bagust, A Boland, R Dickson, Y Dundar, M Moonan, J Oyee, M Blundell, H Davis, A Armstrong, N Thorp
Format: Article
Language:English
Published: NIHR Journals Library 2011-12-01
Series:Health Technology Assessment
Online Access:https://doi.org/10.3310/hta15420

Internet

https://doi.org/10.3310/hta15420

Similar Items